跳至主要内容
临床试验/NCT02532075
NCT02532075终止不适用

The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)

University of Portsmouth1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2016年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
5
试验地点
1
主要终点
Distance walked in the 6 minute walk test

研究概览

简要总结

The purpose of this study is to investigate the effects of performing a breathing muscle warm up before exercise in patients who have chronic obstructive pulmonary disease (COPD). The main aim is to see whether performing a breathing muscle warm up can improve distance walked in a 6 minute walk test and also decrease perceptions of effort and breathlessness.

详细描述

The study will follow a counter-balanced repeated measures design involving six visits to the exercise laboratory. Following pre-screening and familiarisation (visits 1 and 2), participants will perform inspiratory warm up, expiratory warm up, combination warm up and control trials (visits 3 - 6) in a counter-balanced order separated by at least 48 hours between trials.

The four separate sessions will contain: lung function measurements assessed by performing breathing manoeuvres through a mouthpiece (spirometery or body plethysmography) before performing a breathing muscle warm up by breathing against a resistance through a small handheld device (PowerLung). Participants will then be asked perform a second set of lung function measurements and will then be asked to perform a 6 minute walk test wearing a face mask and a portable device (gas analysis), a small device clipped to a finger (pulse oximeter) and wearing a heart rate monitor. During this 6 minute walk test participants will also be asked to rate their perceived effort and level of breathlessness at 60m intervals. Following the test there will be a period of seated rest wearing the face mask and portable device for up to 20 minutes with one more set of lung function measurements.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
盲法
None

入排标准

年龄范围
35 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •A clinical diagnosis of COPD
  • •Aged between 35 and 90 years
  • •Able to fluently read and speak English
  • •Willing and able to sign informed consent
  • •Be able to comply with the procedures outlined for the study

排除标准

  • •Cardiac disease (including arrhythmias)
  • •A medicinal requirement for rate limiting calcium antagonists or beta blockers
  • •Cerebrovascular disease
  • •Peripheral vascular disease
  • •Requirement for supplemental oxygen therapy
  • •CO2 (carbon dioxide) retention
  • •Malignancy
  • •Orthopaedic or neurological conditions effecting the ability to exercise
  • •Clinically apparent heart failure
  • •Renal, hepatic or inflammatory disease
  • •Instability of COPD
  • •Any other reason leading to the inability to complete the requirements of the study.
  • •Additionally: If participants have a resting HR above 120beats.min-1, systolic blood pressure above 180mm Hg or diastolic blood pressure above 100mm Hg prior to the 6 minute walk test they will not be able to commence the test.

研究组 & 干预措施

Inspiratory Warm Up

Experimental

(IWU). Two sets of 15 breaths

干预措施: Inspiratory Warm Up (Other)

Expiratory Warm Up

Experimental

(EWU). Two sets of 15 breaths

干预措施: Expiratory Warm Up (Other)

Combination Warm Up

Experimental

(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory

干预措施: Combination Warm Up (Other)

Control Trial

Other

No warm up

干预措施: Control Trial (Other)

结局指标

主要结局

Distance walked in the 6 minute walk test

时间窗: Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).

Rating of perceived exertion (RPE) in the 6 minute walk test

时间窗: Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).

Measured from 1 minute pre 6 minute walk test to cessation of the test and at 60 metre intervals throughout.

Rating of dyspnoea during the six minute walk test

时间窗: Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).

Measured from 1 minute pre 6 minute walk test to cessation of the test and at 60 metre intervals throughout.

次要结局

  • Heart rate (HR)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Expired gas(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Peripheral arterial oxygen saturation (SpO2)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: maximal inspiratory mouth pressure (MIP)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: maximal expiratory mouth pressure (MEP)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: specific airway resistance (sRaw)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: airway resistance (Raw)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: functional residual capacity (FRCpleth)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: peak inspiratory flow (PIF)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: peak expiratory flow (PEF)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: forced expiratory flow at 25, 50 and 75% maximal vital capacity) (FEF 25, 50, 75)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: forced expiratory volume in one second (FEV1)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: forced vital capacity (FVC)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: residual volume (RV)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: tidal volume (VT)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: total lung capacity (TLC)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: inspiratory residual volume (IRV)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: expiratory residual volume (ERV)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: inspiratory capacity (IC)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)
  • Pulmonary function: inspiratory vital capacity (IVC)(Estimate is 4 weeks per participant to complete all trials. Measured during each trail that is expected to last 1-2 hours. (Trial format is described elsewhere).)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Craig Williamson

PhD Research Student

University of Portsmouth

研究点 (1)

Loading locations...

相似试验